Artelo Biosciences, Inc.
ARTL
$5.98
-$0.21-3.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.37% | 92.56% | 41.69% | 108.51% | 54.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.48% | 13.03% | -26.92% | 158.49% | 25.40% |
| Operating Income | 20.48% | -13.03% | 26.92% | -158.49% | -25.40% |
| Income Before Tax | 24.65% | -24.70% | -10.27% | -175.62% | -32.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.65% | -24.70% | -10.27% | -175.62% | -32.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.65% | -24.70% | -10.27% | -175.62% | -32.39% |
| EBIT | 20.48% | -13.03% | 26.92% | -158.49% | -25.40% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 94.69% | 68.11% | 70.55% | -88.41% | -24.30% |
| Normalized Basic EPS | 94.60% | 68.11% | 78.77% | -78.48% | -20.39% |
| EPS Diluted | 94.69% | 68.11% | 70.55% | -88.41% | -24.30% |
| Normalized Diluted EPS | 94.60% | 68.11% | 78.77% | -78.48% | -20.39% |
| Average Basic Shares Outstanding | 1,321.23% | 291.01% | 274.50% | 46.29% | 6.53% |
| Average Diluted Shares Outstanding | 1,321.23% | 291.01% | 274.50% | 46.29% | 6.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |